AbbVieABBV

Business Snapshot

• AbbVie Inc. (ABBV) is a large-cap biopharmaceutical company listed on the NYSE since December 2012.
• Core business centers on immunology, oncology, neuroscience, and eye-care franchises; key revenue drivers historically include Humira and its successors (Skyrizi, Rinvoq) plus newer oncology assets.
• Asset type is common stock; currency USD; current share price 256.01 after closing the most recent session.

Financial Trends

• Revenue trajectory: Q1-2026 revenue of $15.002 B declined 9.7 % from Q4-2025 ($16.618 B) but rose 3.8 % versus Q3-2025 ($15.776 B) and was down only 2.7 % from Q2-2025 ($15.423 B), indicating a modest sequential rebound after the seasonally strong Q4.
• Operating margin path: 26.60 % (Q1-26) → 90.71 % (Q4-25) → 12.07 % (Q3-25) → 31.73 % (Q2-25). The Q4 spike reflects annual true-ups; underlying run-rate margins have compressed from Q2-25 to Q1-26.
• Net margin: 4.63 % (Q1-26) versus 10.93 % (Q4-25), 1.18 % (Q3-25) and 6.08 % (Q2-25), confirming a step-down from the prior three-quarter average.
• Free-cash-flow trajectory: $3.564 B (Q1-26) versus $17.816 B (Q4-25), $12.927 B (Q3-25) and $6.284 B (Q2-25). Latest quarter FCF is 43 % below Q2-25 and 80 % below Q4-25, signaling a sharp sequential deceleration.
• Balance-sheet strength: Total assets rose to $136.5 B from $134.0 B four periods earlier; shareholders’ equity deteriorated from –$0.183 B to –$6.656 B (latest vs four periods ago), driven by sustained negative retained earnings (–$17.9 B vs –$11.5 B). Current ratio improved modestly to 0.80 from 0.74 over the same span, yet remains sub-1.0.

Financial Health

• Latest period shows adequate liquidity with $9.4 B cash versus $42.1 B current liabilities, but negative working capital (–$8.6 B) and negative equity indicate structural leverage.
• Operating cash generation remains positive ($3.8 B) and comfortably covers the modest $0.3 B capex, supporting the dividend and modest buybacks, yet the sharp drop in FCF versus prior quarters warrants monitoring.
• Rising net-debt-to-equity (–9.7×) and persistent negative equity signal that AbbVie continues to operate with a leveraged capital structure; any sustained margin pressure could tighten credit metrics further.

Insider Activity

• Insider sentiment for the window 31-Mar-2026 to 29-Jun-2026 is Neutral (score 10).
• Twelve insider filings recorded $15,442 of open-market buys and zero sales, producing a small positive net flow.
• No Form 4/5 transactions were parsed for the most recent 30-day slice ending 29-Jun-2026.

Multi-Timeframe Technical Context

• 1-minute: price +1.09 % over 200 bars; RSI-14 59.6 (neutral), MACD slightly negative but flattening; price hugging the upper Bollinger Band ($255.95) with low ATR ($0.68).
• 15-minute: strong +9.07 % advance; RSI-14 67.5 (approaching overbought); MACD positive and price above all key EMAs.
• 1-hour: +13.53 % rally from session low $215.37; RSI-14 59.8, MACD positive but rolling over; price near session high and upper Bollinger ($257.48).
• Daily: +15.41 % over 200 bars, RSI-14 77.5 (overbought), MACD bullish (8.40 > 5.51 signal); price above all moving averages and upper Bollinger ($250.62).
• Weekly: +66.83 % over 145 bars, RSI-14 72.5, MACD positive; price well above rising 20-week SMA ($218.80).
• Monthly: +235 % over 81 bars, RSI-14 68.8, MACD bullish; price at upper Bollinger ($251.11), indicating extended momentum.

Bull / Bear Cases

• Short-term bull: momentum across intraday timeframes remains constructive; price acceptance above $255 could trigger continuation toward $257–$260 zone if volume expands.
• Short-term bear: daily RSI > 77 and proximity to upper Bollinger bands raise odds of mean-reversion or consolidation; failure to hold $253–$254 may invite a quick pullback to the 20-day SMA near $228.
• Long-term bull: diversified late-stage pipeline and cash-flow generation support the dividend; any re-acceleration in Skyrizi/Rinvoq or successful new product